Logo

Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology

Share this

Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology

Shots:

  • LCB to receive $7.25M upfront- $404M as regulatory & commercial milestones and royalties on sales of ADCs product. Takeda licenses rights for LCB’s ConjuAll technology including linker and conjugation platform to develop & commercialize targetted immune-oncology therapies for three targets
  • The focus of the collaboration is to utilize LCB’s ADC technology including linker and payload platform in multiple oncology & immune-oncology therapies
  • LCB’s ConjuAll is ADC technology is a platform providing solutions for site-specific conjugation- linker stability and efficient payload release in the development of ADC- antibiotics- anticoagulants and anticancer therapies

  Ref: BusinessWire | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions